ClinicalTrials.gg

Pancreatic Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,897 studies for Pancreatic Neoplasms across more than 10 countries. 1,002 are recruiting or about to start. 2,770 of them are mainly about Pancreatic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 11 narrower conditions too, such as Adenoma, Islet Cell: 4,171 studies, 1,077 open.

ClinicalTrials.gov finds 5,132 studies for Pancreatic Neoplasms. How that becomes 3,896 here

This page counts the studies the registry files under Pancreatic Neoplasms, and those it files under no condition that list Pancreatic Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 5,132Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −223Filed under a narrower condition, counted on its own pageAdenoma, Islet Cell 93 · Insulinoma 38 · Carcinoma, Pancreatic Ductal 32 · Pancreatic Intraductal Neoplasms 18 · Somatostatinoma 15 · Pancreatic cancer, adult 8 · 4 more
  3. −57List Pancreatic Neoplasms as a condition, but the registry did not file them under itMost often written as “Pancreatic Cancer Resectable” (9), “Pancreatic Cancer Metastatic” (8), and “Pancreatic Cancer Non-resectable” (7). The registry filed them under other conditions only, most often Colorectal Neoplasms (9) and Neoplasms (8).
  4. −956Match it another way282 name it in the title, 9 in a keyword, and 665 by a synonym or other text the search reads.
  5. 3,896The count on this page212 of them list Pancreatic Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
1,567
Recruiting
742
Status unknown
464
Terminated
408
Active, not recruiting
270
Not yet recruiting
234

Phase

Phase 2
1,354
Phase 1
1,102
Phase 3
237
Early Phase 1
92
Phase 4
51

Where

United States
1,851
China
630
France
234
Italy
214
Spain
202
Korea, Republic of
199

Who develops what

Add Pancreatic Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 109 programs from 80 companies, 56 with this as their studies’ main aim; 23 with a live phase 3 study; 31 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Beijing Biotech and Akeso here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GemcitabineRecent, repeated
Evidence
  • NCT07900789 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection” · registered Oct 2026
  • NCT07777211 · Beijing Gene Key Life Technology Co., Ltd · Phase 2 · live · background · “Nab-paclitaxel and Gemcitabine” · registered Aug 2026
  • NCT07701486 · Theriva Biologics SL · Phase 2 · live · background · “Nab-paclitaxel + Gemcitabine” · registered Jul 2026
  • NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Gemcitabine (GEM)” · registered May 2026
  • NCT07578337 · Nelum Corp · Phase 2 · live · background · “Gemcitabine (1000 mg/m2)” · registered May 2026
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed2433 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07777211 · Beijing Gene Key Life Technology Co., Ltd · Phase 2 · live · background · “Nab-paclitaxel and Gemcitabine” · registered Aug 2026
  • NCT07701486 · Theriva Biologics SL · Phase 2 · live · background · “Nab-paclitaxel + Gemcitabine” · registered Jul 2026
  • NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Nab-paclitaxel” · registered May 2026
  • NCT07578337 · Nelum Corp · Phase 2 · live · background · “Nab-paclitaxel (Abraxane)” · registered May 2026
  • NCT07562152 · Immuneering Corporation · Phase 3 · live · comparator · “GnP” · registered Apr 2026
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)1721 studies
LeucovorinRecent, repeated
Evidence
  • NCT07803783 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Leucovorin” · registered Aug 2026
  • NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Leucovorin (Calcium Folinate)” · registered May 2026
  • NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “Leucovorin” · registered Feb 2026
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
  • NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “leucovorin” · registered Sep 2024
Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed67 studies
FluorouracilRecent, repeated
Evidence
  • NCT07803783 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “5 Fluorouracil” · registered Aug 2026
  • NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “5-Fluorouracil” · registered May 2026
  • NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “fluorouracil” · registered Feb 2026
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
  • NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “5-fluorouracil” · registered Sep 2024
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed67 studies
IrinotecanRecent, repeated
Evidence
  • NCT07803783 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Liposomal irinotecan” · registered Aug 2026
  • NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Irinotecan” · registered May 2026
  • NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “Irinotecan” · registered Feb 2026
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
  • NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “Irinotecan” · registered Sep 2024
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)67 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07621718 · Revolution Medicines, Inc. · Phase 3 · live · background · “Oxaliplatin” · registered May 2026
  • NCT07409272 · Astellas Pharma Inc · Phase 3 · live · background · “Oxaliplatin” · registered Feb 2026
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
  • NCT06625320 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “Oxaliplatin” · registered Sep 2024
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Jul 2023
Sanofi35% of its industry studies56 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07900789 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection” · registered Oct 2026
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
  • NCT06821503 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Paclitaxel for injection (albumin bound)” · registered Jan 2025
  • NCT06752811 · Shanghai Yizhong Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel for Injection (albumin bound )” · registered Dec 2024
  • NCT04644068 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Oct 2020
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed44 studies
Modified FOLFIRINOX RegimenRecent, repeated
Evidence
  • NCT07522073 · Incyte Corporation · Phase 3 · live · background · “Investigator's choice of chemotherapy” · registered Apr 2026
  • NCT07444541 · anova innovation limited · Phase 2 · live · background · “mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]” · registered Feb 2026
  • NCT07255404 · BioNTech SE · Phase 2 · live · background · “mFOLFIRINOX” · registered Nov 2025
  • NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “mFOLFIRINOX regimen” · registered May 2024
  • NCT06069778 · BioNTech SE · Phase 2 · background · “mFOLFIRINOX” · registered Sep 2023
—45 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2023
  • NCT05070247 · Takeda · Phase 2 · background · “Pembrolizumab” · registered Sep 2021
  • NCT04332653 · NeoImmuneTech · Phase 2 · background · “pembrolizumab (KEYTRUDA®)” · registered Mar 2020
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)33 studies
CetuximabRecent, repeated
Evidence
  • NCT07644559 · Verastem, Inc. · Phase 2 · live · background · “cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)” · registered May 2026
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
  • NCT06973564 · Jacobio Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Cetuximab” · registered Apr 2025
  • NCT05039177 · Erasca, Inc. · Phase 2 · background · “Cetuximab” · registered Sep 2021
Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004)34 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT07689539 · Qingfeng Pharmaceutical Group Co., Ltd. · Phase 3 · live · comparator · “Chemotherapy” · registered Jun 2026
  • NCT07262567 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Chemotherapy” · registered Nov 2025
  • NCT06962267 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Chemotherapy” · registered Apr 2025
—33 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT04956640 · Eli Lilly and Company · Phase 2 · live · background · “Carboplatin” · registered Jul 2021
  • NCT04644068 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Oct 2020
  • NCT03678883 · Actuate Therapeutics Inc. · Phase 2 · live · background · “Carboplatin.” · registered Sep 2018
Eli Lilly and Company16% of its industry studies22 studies
CisplatinRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Cisplatin” · registered Jul 2023
  • NCT04953962 · CanBas Co. Ltd. · Phase 2 · background · “Cisplatin” · registered Jun 2021
  • NCT03485209 · Pfizer · Phase 2 · live · background · “cisplatin” · registered Mar 2018
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed22 studies
GNP RegimenRecent, repeated
Evidence
  • NCT07563738 · Orion Corporation, Orion Pharma · Phase 2 · live · background · “Gemcitabine and nab-paclitaxel” · registered Apr 2026
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “Gemcitabine and nab-paclitaxel” · registered Nov 2025
  • NCT03417921 · Ability Pharmaceuticals SL · Phase 2 · background · “Gemcitabine and nab-paclitaxel” · registered Jan 2018
—22 studies
PemetrexedRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized22 studies
TemozolomideRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Temozolomide” · registered Mar 2026
  • NCT05417594 · AstraZeneca · Phase 2 · live · background · “Temozolomide (TMZ)” · registered May 2022
Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized22 studies

33 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ivonescimab☆ Track1 live phase-3 study: NCT06953999Akeso
ligufalimab☆ Track1 live phase-3 study: NCT06953999Akeso
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012☆ Track1 live phase-3 study: NCT07823049Evopoint Biosciences Inc.
KRAS G12D Inhibitor VS-7375☆ Track1 live phase-3 study: NCT07262567Genfleet Therapeutics (Shanghai) Inc.
Anti-TF Antibody-drug Conjugate MRG004A☆ Track1 live phase-3 study: NCT07138846Lepu Biopharma Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 109 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (31)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 · Sino Biopharmaceutical Limited · Phase 2 main aimstudied with GemcitabineNCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms — primary endpoint: Progression-free survival (PFS) · 80 enrolled
  • 15 Dec 2026 est.Acoustic Cluster Therapy · EXACT Therapeutics AS · Phase 2 main aimNCT06850623 Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer — primary endpoint: ORR (Overall response rate), defined as the number of participants with measurable disease at baseline who have a confirmed Complete Response or confirmed Partial Response according to RECIST Version 1.1. · 25 enrolled
  • 31 Dec 2026 est.Anti-TF/TOP1i Antibody-drug Conjugate XNW28012 · Evopoint Biosciences Inc. · Phase 2 main aimNCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments — primary endpoint: Ph 1: Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability]. · 350 enrolled

28 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pancreatic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 56 open · Antimetabolites 38 open · Antimitotic agents 23 open · Tyrosine kinase inhibitors (TKIs) 20 open · PARP inhibitors 7 open

Coming up

371studies finish main data collection within a year15 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger. 40 (5%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 59 (8%) take healthy volunteers.

Recruiting studies that take each age, of 742
AgeWomenMen
1029 (4%)29 (4%)
18689 (93%)689 (93%)
30723 (97%)723 (97%)
40730 (98%)730 (98%)
50738 (99%)738 (99%)
65740 (100%)740 (100%)
75716 (96%)716 (96%)
85533 (72%)533 (72%)

Across all 3,897 studies, recruiting or not: 14% stop at 75 or younger and 1% at 65; 5% take children; <1% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pancreatic Neoplasms studies take

Of 394 phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 57 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 145 mo32–68 · 381 studies44 mo31–62 · 172 studies46 mo33–74 · 209 studies
Phase 1/251 mo36–89 · 208 studies47 mo32–88 · 114 studies61 mo40–95 · 94 studies
Phase 257 mo35–80 · 394 studies36 mo26–68 · 69 studies60 mo36–80 · 325 studies
Phase 358 mo36–77 · 84 studies—68 mo39–79 · 46 studies
Interventional, no phase44 mo26–75 · 430 studies—45 mo26–75 · 403 studies
Observational60 mo34–182 · 352 studies—66 mo34–182 · 318 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered15

Show 10 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,897. Browse all 3,897 → or search them.